Veeva Acquires Ostro to Complete Its Pharma Commercial Stack
The $100 million deal adds a patient- and physician-facing AI layer that Veeva's commercial software has never had
Veeva Systems announced Tuesday the acquisition of Ostro, an AI-driven brand engagement platform for life sciences, for approximately $100 million in cash and long-term equity retention grants.
The deal gives Veeva a patient- and physician-facing engagement layer it had not previously owned, rounding out a commercial software portfolio that previously stopped short of the customer-facing layer.
Ostro's platform embeds conversational AI into brand websites, so patients and physicians can get answers to drug questions without waiting for a rep or scrolling through label text. Because the system pulls only from materials that have passed medical-legal-regulatory review, it cannot fabricate information or produce unapproved content.
The company counts more than half of the top 20 global pharmaceutical companies among its clients, including Sanofi, AstraZeneca, Johnson & Johnson, and AbbVie, according to Ostro's website.
Building Toward a Unified Commercial Cloud
Veeva has spent more than a decade building the back-end software that pharma companies use to manage sales, content, and regulatory processes. Its Vault CRM platform now has more than 125 live deployments, with 10 of the top 20 pharmaceutical companies now running on it.
The company reported $3.195 billion in revenue for fiscal year 2026, with a long-term goal of $6 billion by 2030.
What Veeva has not owned, until now, is the part of the experience that patients and doctors actually see. Veeva's AI Agents, launched in December 2025, addressed field rep workflows with tools like a Voice Agent and Pre-call Agent.
But the company had no owned solution for the brand website experience where patients and doctors go looking for drug information independently.
Ostro covers that ground by collecting data from those interactions and feeding it back to brands so they can see what questions are being asked and where people are dropping off. That connection between digital engagement and field activity is central to what Veeva says it intends to build.
"AI has changed how people get information," said Veeva CEO Peter Gassner. "It's no longer about how much information you can put out there, it's about how easy it is for customers to get answers."
The groundwork for integration was already visible before the acquisition closed. In August 2025, Ostro launched Airmark, a tool that converts static pharma marketing emails into conversational AI experiences, with data syncing directly to Veeva's CRM.
That product suggested Ostro had been building toward Veeva well before a deal was on the table.
Ostro CEO Chase Feiger, MD, who co-founded the company in 2019, will continue to lead it as an independent unit inside Veeva. "Brand content should be effortless to access and fully compliant by design," Feiger said. "We built Ostro to remove friction so patients and doctors can get trusted answers with less clicking, thinking, and scrolling."
Veeva said the two platforms will be linked over time through integrations with its Commercial Cloud applications. The goal, Veeva says, is a single view of how a patient or doctor moves from a brand website to a conversation with a sales rep, without the two sides operating in separate systems.